Completed Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients NCT03623243 Conditions Advancing Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +6 more Locations Novartis Investigative Site — Birmingham, Alabama, United States Novartis Investigative Site — Cullman, Alabama, United States Alabama Neurology Associates — Homewood, Alabama, United States Novartis Investigative Site — Tucson, Arizona, United States View all 55 locations View more locations Show fewer locations Loading locations... View Trial Details
